Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Neuroblastoma is the most common extracranial solid childhood tumor, which is believed to originate from primitive neuroblasts giving rise to the sympathetic nervous system. It was previously shown that cyclin D1 (CCDN1) in pediatric neuroblastic tumors (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma) recapitulates its expression during the development of peripheral sympathetic nervous system (PSNS). In the present study, we performed a microarray analysis in order to evaluate the expression of cyclin D1 in neuroblastoma as compared to ganglioneuroma and ganglioneuroblastoma. We first confirmed that comparable levels of cyclin D1 are present in neuroblastoma and fetal neuroblasts. In addition, we observed that neuroblastoma is associated to significantly higher levels of cyclin D1 as compared to both ganglioneuroma and ganglioneuroblastoma. No differences are instead observable between ganglioneuroblastoma and ganglioneuroma. Finally, bioinformatic analysis of cyclin D1-functionally related genes, identified cyclin D2 as an additional marker/etiopathogenic factor in the development of neuroblastoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.acthis.2015.10.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rare Presentation of Cervical Ganglioneuroma: A Case Report.
Cureus
July 2025
Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mohammed VI, Faculty of Medicine and Pharmacy, Abdelmalek Essaadi University, Tangier, MAR.
Ganglioneuromas are rare, benign neoplasms of autonomic origin that represent the most differentiated end of the spectrum of peripheral neuroblastic tumors. Most commonly found in the posterior mediastinum and retroperitoneum, cervical involvement is distinctly uncommon. These tumors usually remain asymptomatic until they exert pressure on surrounding structures.
View Article and Find Full Text PDFRobot-assisted surgery for pediatric tumors: A single-center study of 114 cases.
Surgery
August 2025
Department of Surgical Oncology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, National Center for Children'
Purpose: Although robot-assisted surgery has been widely adopted for adult malignancies, its application in pediatric oncology remains contentious because of limited evidence. This study aims to assess the safety, feasibility, and surgical indications of robot-assisted surgery in pediatric oncology.
Method: A retrospective analysis was conducted on pediatric patients who underwent robot-assisted surgery at the Department of Surgical Oncology, Beijing Children's Hospital, between June 2021 and January 2024.
[An update on the pathology of peripheral neuroblastic tumors].
Ann Pathol
August 2025
Department of Biopathology CHRU-ICL, CHRU de Nancy, Vandœuvre-lès-Nancy, France; Inserm, U1256, NGERE, University of Lorraine, Vandœuvre-lès-Nancy, France. Electronic address:
Peripheral neuroblastic tumors correspond to a generic term for a heterogeneous spectrum of tumors: neuroblastomas, ganglioneuroblastomas (mixed and nodular), and ganglioneuromas. In current practice, the term neuroblastoma is often used because it represents the most frequent and most aggressive tumor component. It is a common tumor in children with heterogeneous morphological, biological and clinical presentations, but with an often unfavorable prognosis.
View Article and Find Full Text PDFPredictive model based on blood cell analysis and coagulation function indicators for neuroblastic tumors staging diagnosis.
Front Oncol
July 2025
Clinical Laboratory, Children's Hospital Affiliated to Shandong University, Jinan, China.
Objective: To explore the diagnostic value of integrating blood cell analysis and coagulation function indicators in the staging of neuroblastic tumors, providing a robust basis for clinical decision-making.
Methods: A retrospective analysis was conducted on 137 pediatric neuroblastic tumors cases (2017-2024) at the Children's Hospital Affiliated to Shandong University. Patients were stratified into localized (INSS 1-2, Group 1) and advanced (INSS 3-4, Group 2) stages according to the INSS classification, with mature ganglioneuroma serving as the control group.
Somatic and mosaic HRAS mutations in pediatric malignant ectomesenchymoma.
J Hum Genet
July 2025
D. Rogachev National Medical Research center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
Malignant ectomesenchymoma (ME), a rare tumor of soft tissues, has a neuroectodermal component of neuroblasts and/or ganglion cells, and a mesenchymal component mostly often represented by rhabdomyoblasts. Considering the peculiar and variable morphological structure of ectomesenchymomas, establishing the correct histological diagnosis can be challenging. The investigation presents 5 cases of ME, including 3 sporadic forms and 2 tumors in patients with neurocutaneous syndrome.
View Article and Find Full Text PDF